Tourmaline Bio, Inc. - Common Stock TRML 深 滬
等待開盤 07-18 09:30:00 美东时间
18.60
+0.060
+0.32%
華盛通- 最 高18.93
- 今 開18.62
- 成交量 8.56万股
- 最 低 18.36
- 昨 收 18.54
- 總市值 4.78亿
- 52周最高 29.7883
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 11.56
- 委 比 56.52%
- 總股本 2568.85万
- 歷史最高 183.082
- 量 比 0.63
- 振 幅 3.07%
- 歷史最低 -6.218
- 每 手 1
- 風險率 8.89%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多新浪财经ESG：TRML MSCI（明晟）ESG评级调降至BBB
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
06-24 07:00
Tourmaline Bio Releases Updated Corporate Presentation
Tourmaline Bio ( ($TRML) ) has provided an announcement. On June 9, 2025, Tourm...
06-09 20:29
Trip.com Posts Weak Earnings, Joins Vipshop, Viking Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures falling aro...
05-20 20:23
Tourmaline Bio posts mid-stage data for anti-inflammatory agent
Shares of Tourmaline Bio (NASDAQ:TRML) fell in the premarket on Tuesday after the company posted topline data from a mid-stage trial for its lead candidate, pacibekitug, in patients with elevated high...
05-20 20:17
Talaris Therapeutics GAAP EPS of -$0.89
Talaris Therapeutics press release (NASDAQ:TRML): Q1 GAAP EPS of -$0.89. – Cash, cash equivalents, and investments of $275.3 million as of March 31, 2025 provide expected cash runway into the second h...
05-02 22:25
美股大行评级 | 潜在涨幅38%！花旗：首予通用汽车(GM)"买入"评级，目标价62美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1122085978711785472.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Piper Sandler：维持Devon Energy(DVN)"超配"评级，目标价从54美元升至56美元</p> <p>• HC Wainwright & Co.：上调Dogwood Therapeutics(
04-24 09:56
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Channel Therapeutics (AMEX:CHRO) stock increased by 86.5% to $2.34 dur...
04-17 20:09
美股大行评级 | Tigress Financial：维持爱彼迎"买入"评级，目标价从195美元升至200美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1107588488073326592.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持ProQR Therapeutics(PRQR)"买入"评级，目标价从10美元升至12美元</p> <p>• Oppenheimer：上调内克塔治疗(NKTR)评级至"跑
03-17 10:10
HC Wainwright & Co. Maintains Buy on Tourmaline Bio, Raises Price Target to $50
HC Wainwright & Co. analyst Yi Chen maintains Tourmaline Bio (NASDAQ:TRML) with a Buy and raises the price target from $49 to $50.
03-14 18:51
Tourmaline Bio’s 2024 Financial Results and Strategic Advances
Tourmaline Bio, Inc. ( ($TRML) ) has released its Q4 earnings. Here is a breakd...
03-14 12:15
